# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: k063347   
B. Purpose for Submission: New application on an approved system

C. Measurand: Anti-cyclic citrullinated peptide (CCP)

D. Type of Test: Microparticle Enzyme Immunoassay (MEIA) Semi-quantitative

E. Applicant: AXIS-SHIELD DIAGNOSTICS, LTD.

F. Proprietary and Established Names: AxSYM $^ \mathrm { \textregistered }$ Anti-CCP Reagent kit $\operatorname { A x S Y M @ }$ Anti-CCP Standard Calibrator kit $\operatorname { A x S Y M @ }$ Anti-CCP Control kit

<table><tr><td rowspan=1 colspan=1>Product Code</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>Regulation Section</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>Antibodies, Anti-Cyclic CitrullinatedPeptide (CCP)(NHX)</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR § 866.5775,Rheumatoid factorimmunological testsystem.</td><td rowspan=1 colspan=1>82 Immunology</td></tr><tr><td rowspan=1 colspan=1>Calibrator, Multi-Analyte Mixture(JIX)</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR § 862.1150</td><td rowspan=1 colspan=1>75 Chemistry</td></tr><tr><td rowspan=1 colspan=1>Quality ControlMaterial (Assayedand Unassayed)(JJY)</td><td rowspan=1 colspan=1>Class I</td><td rowspan=1 colspan=1>21 CFR § 862.1660</td><td rowspan=1 colspan=1>75 Chemistry</td></tr></table>

G. Regulatory Information:

# H. Intended Use:

1. Intended use(s):

$\operatorname { A x S Y M @ }$ Anti-CCP is a Microparticle Enzyme Immunoassay (MEIA) for the semi-quantitative determination of the IgG class of autoantibodies specific to cyclic citrullinated peptide (CCP) in human serum and plasma on the AxSYM System. Detection of anti-CCP antibodies is used as an aid in the diagnosis of Rheumatoid Arthritis (RA) and should be used in conjunction with other clinical information. Autoantibody levels represent one parameter in a multicriterion diagnostic process, encompassing both clinical and laboratory-based assessments.

The AxSYM $^ \mathrm { \textregistered }$ Anti-CCP Standard Calibrators are for the standard calibration of the AxSYM System when used for the semi-quantitative determination the IgG class of autoantibodies specific to cyclic citrullinated peptide (CCP) in human serum and plasma.

The $\operatorname { A x S Y M @ }$ Anti-CCP Controls are for the use in quality control to monitor the accuracy and precision of the $\operatorname { A x S Y M @ }$ Anti-CCP assay when used for the semiquantitative determination of the IgG class of autoantibodies specific to cyclic citrullinated peptide (CCP) in human serum and plasma on the AxSYM System.

2. Indication(s) for use: Same as above   
3. Special conditions for use statement(s): This device is for prescription use only.   
4. Special instrument requirements: For use with AxSYM System Software version 5.0 cleared under k974651

# I. Device Description:

Each AxSYM $^ \mathrm { \textregistered }$ Anti-CCP Reagent kit contains 1 bottle of each component of Conjugate, Microparticles, Sample Diluent and Matrix Cell Blocker.

Conjugate: 1 Bottle $1 2 . 2 \mathrm { m L }$ ) Mouse Anti-Human IgG:Alkaline Phosphatase Conjugate in TRIS buffer containing detergent with protein (Bovine) stabilizers. Minimum concentration $0 . 1 ~ \mu \mathrm { g / m L }$ . Preservative: Sodium Azide. (Reagent Bottle 1) Microparticles: 1 Bottle $( 4 . 8 \mathrm { m L }$ ) CCP-Coated Microparticles in phosphate buffer with protein (Bovine) stabilizers. Minimum concentration: $0 . 1 \%$ solids (w/v). Preservative: Sodium Azide. (Reagent Bottle 2) • Sample Diluent: 1 Bottle $( 2 4 . 7 \mathrm { m L }$ ) Sample Diluent containing detergent with protein (Bovine) stabilizers. Preservative: Sodium Azide. (Reagent Bottle 3) Matrix Cell Blocker: 1 Bottle $5 0 . 2 \mathrm { m L }$ ) Matrix Cell Blocker containing detergent. Preservative: Sodium Azide. (Reagent Bottle 4)

Each Anti-CCP Standard Calibrator kit contains six bottles of $\operatorname { A x S Y M @ }$ Anti-CCP Standard Calibrators $\mathrm { 4 . 3 ~ m L }$ each). Calibrator A is a phosphate buffer with protein (Bovine) stabilizers. Calibrators B-F contains anti-CCP positive human plasma in phosphate buffer with protein (Bovine) stabilizers to yield the concentrations $\mathrm { ( U / m L ) }$ shown in the following table:

<table><tr><td rowspan=1 colspan=1>Standard Calibrator</td><td rowspan=1 colspan=1>Anti-CCP Concentration (U/mL)</td></tr><tr><td rowspan=1 colspan=1>Cal A</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Cal B</td><td rowspan=1 colspan=1>5</td></tr><tr><td rowspan=1 colspan=1>Cal C</td><td rowspan=1 colspan=1>25</td></tr><tr><td rowspan=1 colspan=1>Cal D</td><td rowspan=1 colspan=1>50</td></tr><tr><td rowspan=1 colspan=1>Cal E</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Cal F</td><td rowspan=1 colspan=1>200</td></tr></table>

Each $\operatorname { A x S Y M @ }$ Anti-CCP Control kit contains two bottles $7 . 0 \mathrm { m L }$ each) of controls with one positive and the other negative human plasma in phosphate buffer to yield the following concentrations $\mathrm { ( U / m L ) }$ :

<table><tr><td rowspan=1 colspan=1>Bottle</td><td rowspan=1 colspan=1>Anti-CCPConcentration (U/mL)</td><td rowspan=1 colspan=1>Range (U/mL)</td></tr><tr><td rowspan=1 colspan=1>PositiveControl</td><td rowspan=1 colspan=1>24.0</td><td rowspan=1 colspan=1>14.0 - 34.0</td></tr><tr><td rowspan=1 colspan=1>NegativeControl</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>≤ 3.0</td></tr></table>

Calibrators and controls are sold separately.

# J. Substantial Equivalence Information:

1. Predicate device name(s): DIASTAT™ Anti-CCP   
2. Predicate 510(k) number(s): k023285   
3. Comparison with predicate:

# Similarities

<table><tr><td rowspan=1 colspan=1>Parameter</td><td rowspan=1 colspan=1>Submission DeviceAxis-Shield AxSYM Anti-CCP</td><td rowspan=1 colspan=1>Predicate DeviceAxis-Shield DIASTAT Anti-CCP</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Aid in the diagnosis of RheumatoidArthritis (RA)</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Specimen Type</td><td rowspan=1 colspan=1>Human serum or plasma (sodiumcitrate, lithium heparin)</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Capture Antigen</td><td rowspan=1 colspan=1>Cyclic citrullinated peptide (CCP),second generation</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>StorageConditions</td><td rowspan=1 colspan=1>The AxSYM Anti-CCP ReagentPack, Standard Calibrator Pack andControl Pack must be stored at 2°-8°</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Suggested Cut-off</td><td rowspan=1 colspan=1>5.0 U/mL</td><td rowspan=1 colspan=1>Same</td></tr></table>

# Differences

<table><tr><td rowspan=1 colspan=1>Parameter</td><td rowspan=1 colspan=1>Submission DeviceAxis-Shield AxSYM Anti-CCP</td><td rowspan=1 colspan=1>Predicate DeviceAxis-Shield DIASTAT Anti-CCP</td></tr><tr><td rowspan=1 colspan=1>TechnologyFormat</td><td rowspan=1 colspan=1>Automated, sandwich format,Microparticle EnzymeImmunoassay (MEIA)</td><td rowspan=1 colspan=1>Manual, microtitre plate format,Enzyme-linked ImmunosorbentAssay (ELISA)</td></tr><tr><td rowspan=1 colspan=1>ConjugateAntibody</td><td rowspan=1 colspan=1>Mouse anti-human IgG: alkalinephosphatase</td><td rowspan=1 colspan=1>Alkaline phosphatase-labelledmurine monoclonal antibody tohuman IgG</td></tr><tr><td rowspan=1 colspan=1>Substrate</td><td rowspan=1 colspan=1>4-Methylumbelliferyl phosphate</td><td rowspan=1 colspan=1>Phenolphthalein monophosphate</td></tr><tr><td rowspan=1 colspan=1>Assay End-Point</td><td rowspan=1 colspan=1>Fluorescence</td><td rowspan=1 colspan=1>Color, read at 540-565nm</td></tr><tr><td rowspan=1 colspan=1>Quantitation</td><td rowspan=1 colspan=1>Results are determined from astandard calibration curve (0, 5, 25,50, 100, 200 U/mL) generated andstored on the instrument</td><td rowspan=1 colspan=1>Results are determined from astandard calibration curve (0, 2, 8,30, 100 U/mL) generated on eachmicrotiter plate</td></tr><tr><td rowspan=1 colspan=1>Calibrator Range</td><td rowspan=1 colspan=1>0-200 U/mLAuto-dilute (1/10) up to 2000U/mL</td><td rowspan=1 colspan=1>0-100 U/mL</td></tr><tr><td rowspan=1 colspan=1>Calibration</td><td rowspan=1 colspan=1>Semi-quantitative assay</td><td rowspan=1 colspan=1>Semi-quantitative/qualitative assay</td></tr><tr><td rowspan=1 colspan=1>Calibrators andControls</td><td rowspan=1 colspan=1>Sold separately</td><td rowspan=1 colspan=1>Kit components</td></tr><tr><td rowspan=1 colspan=1>Expected Values inAsymptomaticPopulation</td><td rowspan=1 colspan=1>&lt; 1.0 to 2.9 U/mL in arepresentative study</td><td rowspan=1 colspan=1>0.05 - 3.8 U/mL from a referencepopulation</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

<table><tr><td>STANDARDS</td></tr><tr><td></td></tr><tr><td>Title and Reference Number</td></tr></table>

<table><tr><td>Other Standards</td></tr><tr><td></td></tr></table>

<table><tr><td colspan="5">GUIDANCE</td></tr><tr><td>Document Title</td><td>Office</td><td>Division</td><td>Web Page</td><td></td></tr><tr><td></td><td colspan="4"></td></tr></table>

# L. Test Principle:

The AxSYM $^ \mathrm { \textregistered }$ Anti-CCP is based on Microparticle Enzyme Immunoassay (MEIA)   
technology. The $\operatorname { A x S Y M @ }$ Anti-CCP reagents and sample are pipetted in the   
following sequence:   
SAMPLING CENTER

Sample and all AxSYM Anti-CCP reagents required for one test are pipetted by the Sampling Probe into various wells of a Reaction Vessel (RV). AxSYM Line Diluent and sample are pipetted into the Incubation Well of the RV. The AxSYM Anti-CCP Sample Diluent and diluted sample are pipetted into the Sample Well of the RV. • The AxSYM Anti-CCP Matrix Cell Blocker is pipetted into the Buffer Well of the RV. The AxSYM Anti-CCP Mouse Anti-Human IgG:Alkaline Phosphatase Conjugate is pipetted into Reagent Well 3 of the RV. AxSYM Line Diluent and CCP-Coated Microparticles are pipetted into Reagent Well 2 of the RV. A reaction mixture is formed by combining diluted sample and diluted microparticles coated with CCP in Reagent Well 1 of the RV. When anti-CCP antibody is present in the sample, it binds to the CCP-Coated Microparticles, forming antigen-antibody complexes on the microparticles. The RV is immediately transferred into the Processing Center. Further pipetting is done in the Processing Center by the Processing Probe.

# PROCESSING CENTER

An aliquot of Matrix Cell Blocker is transferred to the Matrix Cell. An aliquot of the reaction mixture, containing microparticles and bound antigen-antibody complex, is transferred to the Matrix Cell. The microparticles bind irreversibly to the glass fiber matrix. The Matrix Cell is washed to remove materials not bound to the microparticles. The AxSYM Anti-CCP Mouse Anti-Human IgG:Alkaline Phosphatase Conjugate is dispensed onto the Matrix Cell and it binds with the antigenantibody complexes.   
• The Matrix Cell is washed to remove conjugate not bound to the microparticles. The substrate, 4-Methylumbelliferyl Phosphate, is added to the Matrix Cell The alkaline phosphatase-labeled conjugate catalyzes the removal of a phosphate group from the substrate, yielding the fluorescent product, 4- Methylumbelliferone. This fluorescent product is measured by the MEIA optical assembly.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility: Four samples covering the measuring range of the device were assayed in replicates of two at two separate times of the day for twenty days $( \mathrm { n } { = } 8 0 )$ . Testing was performed on two AxSYM Systems, using one reagent lot. The precision acceptance criteria for total $\% \mathrm { C V }$ and within-run $\% \mathrm { C V }$ was $< 1 5 \%$ . Data from the studies are summarized below:

<table><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=1>Within run%CV</td><td rowspan=1 colspan=1>Total%CV</td></tr><tr><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>5.2</td><td rowspan=1 colspan=1>6.9</td><td rowspan=1 colspan=1>9.3</td></tr><tr><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>10.7</td><td rowspan=1 colspan=1>11.1</td></tr><tr><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>13.8</td><td rowspan=1 colspan=1>7.1</td><td rowspan=1 colspan=1>8.4</td></tr><tr><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>15.0</td><td rowspan=1 colspan=1>5.7</td><td rowspan=1 colspan=1>7.7</td></tr><tr><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>24.4</td><td rowspan=1 colspan=1>7.0</td><td rowspan=1 colspan=1>8.6</td></tr><tr><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>25.6</td><td rowspan=1 colspan=1>6.6</td><td rowspan=1 colspan=1>8.3</td></tr><tr><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>139.8</td><td rowspan=1 colspan=1>6.8</td><td rowspan=1 colspan=1>10.0</td></tr><tr><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>149.7</td><td rowspan=1 colspan=1>7.1</td><td rowspan=1 colspan=1>8.5</td></tr></table>

# b. Linearity/assay reportable range:

Linearity testing was demonstrated by testing five high patient sample pools, with anti-CCP concentrations between 100 and $2 0 0 \mathrm { U / m L }$ . These samples were serially diluted with AxSYM Anti-CCP Negative control at the following dilutions: 1:2, 1:4, 1:6, 1:8, and 1:10. Each dilution was assayed in triplicate and a median is calculated. Data was analyzed using linear regression analysis (x-axis: expected concentration and y-axis: actual concentration). The data showed the following regression equation:

Sample Pool 1 $\mathrm { y } = 1 . 0 8 4 2 \mathrm { x } + 2 . 3 2 9 4$ , $\mathrm { r } ^ { 2 } = 0 . 9 9 1$ Sample Pool 2 $\mathrm { y } = 1 . 0 0 2 5 \mathrm { x } + 4 . 6 5 6 3$ , $\mathrm { r } ^ { 2 } { = } 0 . 9 8 7 3$ Sample Pool 3 $\mathrm { y } = 0 . 9 5 0 7 \mathrm { x } + 6 . 6 9 8 9$ , $\mathrm { r } ^ { 2 } = 0 . 9 8 6 9$ Sample Pool 4 $\mathrm { y } = 1 . 0 2 8 8 \mathrm { x } + 3 . 1 9 2 3 ,$ , $\mathrm { r } ^ { 2 } = 0 . 9 8 1 3$ Sample Pool 5 $\mathrm { y } = 1 . 0 0 0 \mathrm { x } + 1 . 9 6 5 8 ,$ $\mathrm { r } ^ { 2 } = 0 . 9 9 0 3$

The AxSYM Anti-CCP assay showed linearity from 0 to $2 0 0 \mathrm { U / m L }$

In addition, an automated dilution protocol was designed to assist in quantitation of test results using the AxSYM system. The AxSYM system performs a 1:10 dilution of the specimen prior to analysis. The system automatically calculates the concentration of the diluted specimen and reports the result. Five high sample pools were used in this study. Each sample was diluted manually and auto-dilute using Anti-CCP Negative Control. The assay was designed to have a mean auto-dilute recovery of $10 0 \pm 2 0 \%$ . The $\%$ recoveries for the five sample pools were 107.3, 90.0, 86.3, 91.3, 100.2, and 95.0. The results support the use of both automated and manual 1:10 dilution for the AxSYM Anti-CCP assay.

# High dose hook effect

The possibility of high dose hook effect occurring when using the device was evaluated with two serum samples with concentrations above the assay range (1200U/mL and $2 4 0 0 \mathrm { U / m L }$ ). The samples were analyzed on two AxSYM instruments in triplicate with two reagent lots. No hook effect was observed at concentrations 12 times that of Calibrator F $( 2 0 0 \mathrm { U / m L } )$ ).

c. Traceability, Stability, Expected values (controls, calibrators, or methods): An international reference material for anti-CCP antibodies is not available. The calibrators and controls are assigned relative arbitrary Axis-Shield units $\mathrm { ( U / m L ) }$ .

The AxSYM Anti-CCP Reference Calibrators were manufactured using a pool of high titer anti-CCP positive plasmas that has been assigned a value in $\mathrm { U / m L }$ . The AxSYM Anti-CCP Standard Calibrators were prepared from an anti-CCP stock (positive plasma) diluted in Calibrator diluent. This is tested by rate matching to the Reference Calibrator and should be within the target range $0 \mathrm { f } \pm 2 . 5 \%$ . If acceptable, this becomes Calibrator F and is then further diluted to produce calibrators B-E.

# Storage conditions

The AxSYM Anti-CCP Reagent Pack must be stored at $2 { - } 8 ^ { \circ } \mathrm { C }$ . When stored and handled as directed, reagents are stable until the expiration date.

# d. Detection limit:

The AxSYM assay is designed to have a mean analytical sensitivity/limit of blank (LoB) of $\leq 1 . 0 \mathrm { U / m L }$ . The LoB was calculated as the concentration at the $9 5 ^ { \mathrm { t h } }$ percentile above the Standard Calibrator A $( 0 . 0 \mathrm { U / m L } )$ ) and was found to be $0 . 0 6 7 \mathrm { U / m L }$ . The design specification $( \leq 1 . 0 \mathrm { U / m L } )$ was met.

# e. Analytical specificity:

Interference: Interference testing was performed using guidance supplied by CLSI EP7-A, “Interference testing in Clinical Chemistry”. No significant interference was observed in:

• Hemoglobin up to $5 0 0 \mathrm { m g / d L }$ • Bilirubin up to $2 0 \mathrm { m g / d L }$ • Triglycerides up to $1 5 0 0 \mathrm { m g / d L }$ $\bullet$ Total Protein up to $1 2 { \mathrm { g / d L } }$ • Rheumatoid Factor up to $2 0 0 \ : \mathrm { I U / m L }$ • RBC up to $0 . 4 \%$

# Crossreactivity

To assess the potential cross-reactivity of the CCP antigen used in the AxSYM Anti-CCP assay with other autoantibodies, the assay was evaluated with 16 samples, all with high levels of various autoantibodies and negative for CCP. The following autoantibodies (2 samples each) were tested: SSA, SSB, RNP, dsDNA, Jo-1, and Ribosomal-P. The study showed no significant cross-reactivity of the CCP antigen with any of these autoantibodies.

f. Assay cut-off: See Expected Value.

2. Comparison studies:

a. Method comparison with predicate device:

Nine hundred thirty one (931) specimens were tested at Axis-Shield using the $\operatorname { A x S Y M @ }$ Anti-CCP assay and its predicate device, DIASTAT™ Anti-CCP assay. Specimens were received from five sites covering a range of relevant disease states. Sample distribution and percent concordance between the two devices for each disease group are shown below:

<table><tr><td rowspan=1 colspan=1>Disease Group</td><td rowspan=1 colspan=1>Total N</td><td rowspan=1 colspan=1>%American</td><td rowspan=1 colspan=1>%European</td><td rowspan=1 colspan=1>%Concordance</td></tr><tr><td rowspan=1 colspan=1>Asymptomatic Healthy</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>EBV</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Infectious disease</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>SLE</td><td rowspan=1 colspan=1>76</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>86</td><td rowspan=1 colspan=1>99</td></tr><tr><td rowspan=1 colspan=1>Sjögren&#x27;s Syndrome</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Scleroderma</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Polymyositis/Dermatomyositis</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>67</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Osteoarthritis</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Psoriatic Arthritis</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Inflammatory Polyarthritis</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Ankylosing Spondylitis</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Rheumatoid arthritis</td><td rowspan=1 colspan=1>529</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>82</td><td rowspan=1 colspan=1>95</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>931</td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=1>96</td></tr></table>

The following table summarized the $\%$ concordance between the two assays:

RA (n = 529)

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>DIASTAT</td></tr><tr><td rowspan=1 colspan=1>AxSYM</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>384</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>122</td></tr></table>

Total Agreement $( 9 5 \% \thinspace \mathsf { C l } ) = 9 5 . 7 \%$ (93.5-97.2%) Positive Agreement $( 9 5 \% \mathsf { C l } ) = 9 4 . 3 \%$ (91.6-96.4%) Negative Agreement $( 9 5 \% \mathsf { C l } ) = 1 0 0 \%$ (97.6-100%)

Non-RA (n = 402)

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>DIASTAT</td></tr><tr><td rowspan=1 colspan=1>AxSYM</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>379</td></tr></table>

Total Agreement $( 9 5 \% \mathsf { C l } ) = 9 9 . 5 \%$ (98.2-99.9%) Positive Agreement $( 9 5 \% \mathsf { C l } ) = 9 5 . 5 \%$ (77.2-99.9%) Negative Agreement $( 9 5 \% \thinspace \mathsf { C l } ) = 9 9 . 7 \%$ (98.5-100%)

# All Samples (n = 931)

Total Agreement $( 9 5 \% \mathsf { C l } ) = 9 7 . 3 \%$ (96.1-98.3%)

Positive Agreement $( 9 5 \% \mathsf { C l } ) = 9 4 . 4 \%$ (91.8-96.4%)

Negative Agreement $( 9 5 \% \mathsf { C l } ) = 9 9 . 8 \%$ (98.9-100%)

b. Matrix comparison:

Matrix comparison studies using matched serum (clot), serum separator, EDTA, lithium and sodium citrate plasma samples covering the dynamic range were performed on the AxSYM instrument using $\operatorname { A x S Y M @ }$ AntiCCP assay. The results of the linear regression analyses are seen on the table below.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Slope(95% CI)</td><td rowspan=1 colspan=1>Intercept(95% CI)</td><td rowspan=1 colspan=1>CorrelationCoefficient</td></tr><tr><td rowspan=1 colspan=1>Serum (clot vs.Serum separator)</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>1.0618(0.9943-1.1294)</td><td rowspan=1 colspan=1>-1.2470(-4.8136-2.3197)</td><td rowspan=1 colspan=1>1.00</td></tr><tr><td rowspan=1 colspan=1>Serum vs.Lithium Heparin</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0.9531(0.9246-9816)</td><td rowspan=1 colspan=1>0.3433(-11598-1.8465)</td><td rowspan=1 colspan=1>1.00</td></tr><tr><td rowspan=1 colspan=1>Serum vs.Sodium Citrate</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0.9880(0.9617-1.0142)</td><td rowspan=1 colspan=1>0.3122(-1.0726-1.6970)</td><td rowspan=1 colspan=1>1.00</td></tr><tr><td rowspan=1 colspan=1>Serum vs. EDTA</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0.9452(0.9211-0.9693)</td><td rowspan=1 colspan=1>0.4536(-0.8189-1.7261)</td><td rowspan=1 colspan=1>1.00</td></tr></table>

3. Clinical studies:

a. Clinical Sensitivity and Specificity Using the same samples from the method comparison study, $\%$ sensitivity and specificity were calculated. The following results were obtained:

<table><tr><td rowspan=1 colspan=1>DiseaseGroup</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Anti-CCP positive</td><td rowspan=1 colspan=1>%Sensitivity</td><td rowspan=1 colspan=1>% Specificity</td></tr><tr><td rowspan=1 colspan=1>All RAsamples</td><td rowspan=1 colspan=1>529</td><td rowspan=1 colspan=1>382</td><td rowspan=1 colspan=1>72.2</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>All Non-RAsamples</td><td rowspan=1 colspan=1>402</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>94.5</td></tr></table>

The lower sensitivity of $7 2 . 2 \%$ was accepted for the following reasons:

1. Anti-CCP assays from different manufacturers showed variable ranges from $69 \%$ to $8 7 . 8 \%$ .   
2. Literature showed sensitivity ranging from $65 \%$ to $8 5 \%$ in established RA depending on cohort tested.

References:

Autoantibodies to citrullinated antigens in (early) rheumatoid arthritis. W.J. van Venrooij, A.J.W. Zendman, GJN Pruijn. Autoantibody Reviews: 6 (2006); 37-41.

Anti-cyclic citrullinated peptide antibodies: diagnostic, predictive and monitoring value in RA. PH Schur. Int. J. Advances in Rheumatogy: 3 (2005); 77-83.

Diagnostic and predictive value of anti-CCP antibodies in rheumatoid arthritis: a systematic literature review. J Avouac, L Gossec, M Dougados. Ann. Rheum. Dis. (2006). Online: doi:10.1136/ard.2006.051391.

b. Other clinical supportive data (when a. is not applicable): None

4. Clinical cut-off: Not applicable

5. Expected values/Reference range:

In a representative study, 100 serum specimens from asymptomatic healthy donors with an age range of 19-73 years, comprised of males $( \mathrm { n } { = } 5 1 )$ ) and females $( \mathrm { n } { = } 4 9 )$ , were tested in the AxSYM Anti-CCP assay. No differences attributable to gender or age were observed. Specimen values range from $< 1 . 0$ to $2 . 9 \mathrm { U } / \mathrm { m L }$ . On the basis of this reference population data, the suggested cut-off is $5 . 0 \mathrm { U / m L }$ . Values $\ge 5 . 0 \ \mathrm { U / m L }$ is considered positive and $\leq 5 . 0 \mathrm { U / m L }$ is considered negative.

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.